Pregabalin Capsule
Product Images NDC 63629-8199

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8199). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298199)

Label for Pregabalin Capsules USP, 25 mg strength, repackaged by Bryant Ranch Prepack, Inc. The label includes the NDC 63629-8199-01, the BRP Pharmaceuticals logo, and indicates a 30 capsule count. It also states storage instructions and a warning to keep out of reach of children.*

FDA Label Image

Label (Lbl6362981992)

Pregabalin 25 mg capsule label by Bryant Ranch Prepack, featuring a red capsule indicator and black text. The label includes storage instructions (20°-25°C), a comparison to Lyrica 25 mg capsules by ScieGen Pharmaceuticals, a quantity of 30 capsules, and an NDC number 6362981991. The label states RX only and includes a barcode.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: pregabalin 200 mg three times a day, pregabalin 100 mg three times a day, pregabalin 25 mg three times a day, and placebo.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph depicting the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. It compares Pregabalin 100 mg three times a day with a placebo, showing higher patient improvement percentages for Pregabalin across various levels of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin at 300 mg, 150 mg, and 75 mg taken twice a day, along with a placebo group. Percent improvement in pain ranges from over 0% to 100% on the x-axis, and percent of patients improved from 0% to 100% on the y-axis.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin at 200 mg three times a day, Pregabalin at 100 mg three times a day, and placebo. The graph shows three distinct lines corresponding to each treatment group on a scale from 0 to 100 percent on both axes.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line chart comparing the percent of patients improved against percent improvement in pain from baseline, showing three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain, and the y-axis represents percent of patients improved.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across dosing groups in Study E1 and Study E3. Study E1 groups include placebo, 50 mg/day BID, 150 mg/day BID, 300 mg/day BID, and 600 mg/day BID. Study E3 groups include placebo, 300 mg/day BID, and 600 mg/day TID. Responders rates increase with dose in both studies, with statistical significance noted versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line chart showing seizure reduction (median percentage change from baseline) versus dose (mg/day) for four different studies labeled E1 BD, E2 TID, E3 BD, and E3 TID. The chart includes data points with significant p-values, highlighting dose-dependent seizure reduction effects for Pregabalin with various dosing schedules.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 800mg daily dose, 450mg daily dose, 300mg daily dose, and placebo, with separate lines representing each group to illustrate treatment efficacy.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier curve showing the estimated percentage of subjects without LTR over 180 days for Pregabalin versus placebo. The solid line represents Pregabalin, and the dashed line represents placebo, with percentages on the Y-axis and days on the X-axis.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over various thresholds from baseline to week 12. The graph shows two lines: one solid line for Pregabalin and one dashed line for Placebo, plotted against percent improved on the x-axis from >0 to 100, and percent of subjects improved on the y-axis from 0 to 100.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved on Pregabalin versus Placebo. The x-axis shows the percent improvement from baseline to week 16 BOCF, and the y-axis indicates the percent of subjects improved. Two curves are plotted: a solid line for Pregabalin and a dotted line for Placebo, showing higher improvement rates for Pregabalin across most percentiles.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula showing creatinine clearance (CLcr) calculation: (140 - age in years) multiplied by weight in kilograms, divided by 72 times serum creatinine in mg/dL, with a multiplication factor of 0.85 for female patients. The formula is used in pharmacokinetic dosing considerations.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of Pregabalin, showing its molecular components including an amine group, carboxylic acid group, and a branched carbon chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.